Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) (DBCOND0072553)

Identifiers

Synonyms

Peripheral T-Cell Lymphoma (PTCL NOS) / Peripheral T-cell Lymphoma, NOS / Peripheral T-cell Lymphoma (Not Otherwise Specified) / Peripheral T-cell Lymphoma NOS / Peripherial T Cell Lymphoma,Not Otherwise Specified / Peripheral T-cell Lymphoma Unspecified / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Peripheral T-cell Lymphoma-not Otherwise Specified / Peripheral T-cell lymphoma unspecified NOS / Peripheral T Cell Lymphoma Unspecified / Peripheral T Cell Lymphoma, Unspecified / PTCL, NOS / PTCL-NOS / Peripheral T-cell lymphoma, not elsewhere classified / Peripheral T-cell lymphoma (morphologic abnormality) / Lymphoma, T-Cell, Peripheral / Peripheral T-cell lymphoma (disorder)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04021082	CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)	Cerdulatinib	treatment	2 / 3	withdrawn
NCT02742727	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma	Natural Killer Cell	treatment	1 / 2	unknown_status
NCT00901147	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma	Bortezomib Bortezomib D-mannitol Panobinostat	treatment	2	completed
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Tislelizumab	treatment	2	completed
NCT01719835	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study	Cisplatin Cyclophosphamide Doxorubicin Gemcitabine Methylprednisolone Prednisolone Vincristine	treatment	2	unknown_status
NCT03905135	Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies	Avelumab Interleukin-15, human recombinant	treatment	1	completed
NCT01746992	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma	Cyclophosphamide Doxorubicin Etoposide Ifosfamide Methotrexate Pirarubicin Prednisone Vincristine	treatment	4	unknown_status
NCT05208853	An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma	No drug interventions	treatment	0	unknown_status
NCT00704691	Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas	Lenalidomide	treatment	0	terminated
NCT01198665	RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas	Cyclophosphamide Doxorubicin Everolimus Prednisolone Vincristine	treatment	1 / 2	completed
NCT00725231	Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP	Alemtuzumab	treatment	3	unknown_status
NCT06561048	Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma	Belinostat Pralatrexate Soquelitinib	treatment	3	recruiting
NCT02533700	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL	No drug interventions	treatment	2	unknown_status
NCT03590574	Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma	No drug interventions	treatment	1 / 2	recruiting
NCT05821192	Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.	Cisplatin Dexamethasone Gemcitabine Rituximab	treatment	Not Available	recruiting
NCT04803201	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma	Azacitidine Cyclophosphamide Doxorubicin Duvelisib Etoposide Prednisone Vincristine	treatment	2	recruiting
NCT01787409	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	No drug interventions	treatment	Not Available	recruiting
NCT02652715	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	No drug interventions	basic_science	Not Available	completed
NCT03113500	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	Beta-D-Glucose Brentuximab vedotin Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Prednisone	treatment	2	active_not_recruiting
NCT03040206	Risk Stratification of Nodal PTCL	No drug interventions	Not Available	Not Available	completed
NCT05978141	A Registry for People With T-cell Lymphoma	No drug interventions	Not Available	Not Available	recruiting
NCT06508463	Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma	Cemiplimab Human interferon beta Ipilimumab Sodium iodide	treatment	1	recruiting
NCT02561273	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Beta-D-Glucose Cortisone Cyclophosphamide Doxorubicin Etoposide Lenalidomide Prednisone Sulfate ion Vincristine	treatment	1 / 2	completed
NCT04423926	Lenalidomide in Combination With CHOP in Patients With Untreated PTCL	Cyclophosphamide Doxorubicin Lenalidomide Prednisolone Vincristine	treatment	1 / 2	recruiting
NCT02223208	Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas	Cyclophosphamide Doxorubicin Etoposide Prednisone Romidepsin Vincristine	treatment	1 / 2	active_not_recruiting